Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006081 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00006081: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00006081 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006081, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 and paclitaxel in treating patients who have unresectable locally advanced or metastatic stomach cancer.
Interventions
- DRUG Paclitaxel (Taxol)
- DRUG Bryostatin-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2000-06 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006081
The ClinicalTrials.gov registry entry for NCT00006081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel (Taxol) is the first listed.
NCT00006081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006081 about?
NCT00006081 is a clinical study titled "Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 and paclitaxel in treating patients who have u...
What is the current status of trial NCT00006081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2000-06. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00006081?
The interventions under investigation include: Paclitaxel (Taxol) (DRUG), Bryostatin-1 (DRUG).
Who is sponsoring clinical trial NCT00006081?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.